Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

154.98 +3.17 (+2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

5 Safe Stocks Under $40 to Buy Immediately ↗

August 21, 2023

Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 17, 2023

Via Benzinga

Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia ↗

August 17, 2023

Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9

Via Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

August 11, 2023

Via Benzinga

How Is The Market Feeling About Gilead Sciences? ↗

August 10, 2023

Via Benzinga

2 High-Yield Dividend Stocks to Buy on the Dip ↗

August 08, 2023

The market may have been a bit too harsh on these stocks.

Via The Motley Fool

Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript ↗

August 04, 2023

GILD earnings call for the period ending June 30, 2023.

Via The Motley Fool

Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth? ↗

August 03, 2023

Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs.

Via Investor's Business Daily

The 3 Best Biotech Stocks to Buy in August ↗

August 09, 2023

Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.

Via InvestorPlace

Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation ↗

August 04, 2023

Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by...

Via Benzinga

Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review ↗

August 04, 2023

Amazon, ELF and CAT were earnings winners, but there were big losers too.

Via Investor's Business Daily

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

July 31, 2023

Via Benzinga

Expert Ratings for Gilead Sciences ↗

July 24, 2023

Via Benzinga

Peering Into Gilead Sciences's Recent Short Interest ↗

July 19, 2023

Via Benzinga

US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month ↗

August 03, 2023

Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.

Via Benzinga

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗

August 01, 2023

Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.

Via InvestorPlace

3 Stocks Retirees Should Absolutely Love ↗

July 29, 2023

These stocks offer solid income plus more.

Via The Motley Fool

Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer ↗

July 24, 2023

Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility

Via Benzinga

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

July 18, 2023

Via Benzinga

Price Over Earnings Overview: Gilead Sciences ↗

July 17, 2023

Via Benzinga

Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling ↗

July 24, 2023

The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives ↗

July 23, 2023

DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing...

Via Talk Markets

2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street ↗

July 20, 2023

The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future.

Via The Motley Fool

The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023 ↗

July 19, 2023

The market is soaring, but there is still time to buy these seven undervalued Nasdaq stocks before they head higher.

Via InvestorPlace

3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗

July 19, 2023

It helps to offer products everyone needs.

Via The Motley Fool

SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? ↗

July 18, 2023

Read the latest report on NanoViricides here.

Via Benzinga

Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash ↗

July 17, 2023

These stocks are built to withstand a bear market.

Via The Motley Fool

FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment ↗

July 14, 2023

The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,

Via Benzinga

7 Tech Stocks to Watch on July 14 ↗

July 12, 2023

Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 12, 2023

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Starting at $3.75/week.

Subscribe Today